For in vitro diagnostic use. Others Elecsys sFlt-1 IVD Elecsys® sFlt-1 CPS_000512 09 015 388 190 9 015 388 190 09015388190 9015388190 09015388190 sFLT1 Elecsys E2G 100 V2 Elecsys sFlt-1 07613336172094 Reagents, kits 100 tests cobas e 402/801 true 05 109 523 190 5 109 523 190 05109523190 5109523190 05109523190 sFLT1 Elecsys cobas e 100 Elecsys sFlt-1 04015630924271 Reagents, kits 100 tests cobas e 411/601/602 true 09 015 353 160 9 015 353 160 09015353160 9015353160 09015353160 sFLT1 Elecsys cobas e 100 V2 Elecsys sFlt-1 07613336230671 Reagents, kits 100 tests cobas e 411/601/602 true 07 027 818 190 7 027 818 190 07027818190 7027818190 07027818190 sFLT1 Elecsys E2G 100 Elecsys sFlt-1 04015630940509 Reagents, kits 100 tests cobas e 402/801 true 09015388501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783E10E FF000000077EEC0E 09015388190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 05109523500 Elecsys sFlt-1 en 11 FF0000000483ED0E FF000000004C570E 05109523190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of soluble fms‑like tyrosine kinase‑1 (sFlt‑1) in human serum.The Elecsys sFlt‑1 assay is used in combination with the Elecsys PlGF assay to determine the sFlt‑1/PlGF ratio. The sFlt‑1/PlGF ratio is intended for use as an aid in the diagnosis of preeclampsia in conjunction with other diagnostic and clinical information.In addition the sFlt‑1/PlGF ratio is intended for use as an aid in short-term prediction of preeclampsia (rule-out and rule-in) in pregnant women with suspicion of preeclampsia in conjunction with other diagnostic and clinical information.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 09015353501 Elecsys sFlt-1 and Elecsys PIGF sFlt-1/PIGF ratio for preeclampsia en 1 FF0000000783DE0E FF0000000781B10E 09015353160 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassays for the in vitro quantitative determination of the soluble fms‑like tyrosine kinase‑1/placental growth factor (sFlt‑1/PlGF) ratio in human serum. The sFlt‑1/PlGF ratio is indicated as an aid in the risk assessment of pregnant women, with a singleton pregnancy (23+0 to 34+6/7 weeks’ gestation) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), to develop preeclampsia with severe features within 2 weeks from testing. The sFlt‑1/PlGF ratio should be used in conjunction with clinical assessment and routine laboratory testing. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027818500 Elecsys sFlt-1 en 6 FF000000050D4D0E FF00000004EE980E 07027818190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of soluble fms‑like tyrosine kinase‑1 (sFlt‑1) in human serum.The Elecsys sFlt‑1 assay is used in combination with the Elecsys PlGF assay to determine the sFlt‑1/PlGF ratio. The sFlt‑1/PlGF ratio is intended for use as an aid in the diagnosis of preeclampsia in conjunction with other diagnostic and clinical information.In addition the sFlt‑1/PlGF ratio is intended for use as an aid in short-term prediction of preeclampsia (rule-out and rule-in) in pregnant women with suspicion of preeclampsia in conjunction with other diagnostic and clinical information.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® sFlt-1

Overview

Ordering Information

Technical Documents

Access important product documentation including relevant certificates and other resources.

Compatible Instruments

Related products

Contact us